Results 141 to 150 of about 1,866 (169)
Some of the next articles are maybe not open access.
Journal of dermatology (Print)
Bimekizumab, an interleukin (IL)‐17A/IL‐17F inhibitor, is effective for moderate‐to‐severe psoriasis. However, long‐term maintenance of early treatment outcomes is not examined in real‐world settings, with no analyses stratified by dosing intervals ...
Marina Onda +4 more
semanticscholar +1 more source
Bimekizumab, an interleukin (IL)‐17A/IL‐17F inhibitor, is effective for moderate‐to‐severe psoriasis. However, long‐term maintenance of early treatment outcomes is not examined in real‐world settings, with no analyses stratified by dosing intervals ...
Marina Onda +4 more
semanticscholar +1 more source
Bimekizumab (Bimzelx) for Psoriasis
The Medical Letter on Drugs and TherapeuticsThe FDA has approved the injectable interleukin (IL)-17A/17F antagonist bimekizumab-bkzx (Bimzelx – UCB) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic treatment or phototherapy. Bimekizumab is the first IL-17A/17F antagonist to be approved in the US.
openaire +2 more sources
Expert Opinion on Drug Safety
Introduction Bimekizumab is the latest biologics approved for the management of moderate-to-severe plaque psoriasis. Its unique mechanism of action simultaneously inhibition of interleukin (IL)17A and IL17F] offers a potentially deeper suppression of ...
M. Megna +7 more
semanticscholar +1 more source
Introduction Bimekizumab is the latest biologics approved for the management of moderate-to-severe plaque psoriasis. Its unique mechanism of action simultaneously inhibition of interleukin (IL)17A and IL17F] offers a potentially deeper suppression of ...
M. Megna +7 more
semanticscholar +1 more source
Journal of dermatology (Print)
Long‐term (2‐year) effectiveness of bimekizumab for psoriasis is unknown in real‐world practice. This study is aimed at evaluating 104‐week real‐world effectiveness of bimekizumab in patients with psoriasis, stratified by the presence or absence of prior
Yohei Takahashi +4 more
semanticscholar +1 more source
Long‐term (2‐year) effectiveness of bimekizumab for psoriasis is unknown in real‐world practice. This study is aimed at evaluating 104‐week real‐world effectiveness of bimekizumab in patients with psoriasis, stratified by the presence or absence of prior
Yohei Takahashi +4 more
semanticscholar +1 more source
Bimekizumab for Hidradenitis Suppurativa: Pathophysiology and Promising Interventions.
Cutis (New York, N.Y.)Hidradenitis suppurativa (HS) is a debilitating dermatologic disorder characterized by recurrent inflammation that affects the apocrine glands and hair follicles and profoundly impacts patients' quality of life.
Mohammad Fardos +2 more
semanticscholar +1 more source
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception ...
openaire +1 more source